New Frontiers in 3D Cell Technologies

Fostering discussion of transformative 3D in vitro cell technologies  from advanced disease modeling to organ-on-a-chip solutions

KOL Roundtables ●  Symposia ●  Curated News Digests

Are you ready for the future of preclinical drug testing?

Organ on a chip systems | scalable 3D disease modeling platforms | animal testing alternatives | highly predictive drug safety screening

Join the conversion.  Help shape the future.

New Frontiers in 3D Technologies is going digital!  This fall we’re introducing a virtual roundtable series featuring key opinion leaders who are on a mission to transform drug discovery and safety testing. Next year, we’ll host a virtual symposium that will bring together pharma and biotech thought-leaders, research scientists, and regulatory experts to discuss innovative new 3D cell technologies for drug efficacy and safety testing.  We are also launching a curated news digest focused on 3D in vitro breakthroughs.  Our aim is to make it easy and convenient for us all to stay in touch and stay informed during this pandemic and beyond. 

  • Learn about practical applications for the latest generation of 3D in vitro models that have successfully transitioned from R&D evaluations to indispensable for everyday use in industry
  • Discuss 3D technology trends and real-world implementation challenges
  • Discover disease modeling platforms, assay strategies, and readout techniques that could transform how your organization does drug discovery and development
  • Debate how best to apply emerging tools for organ-on-a-chip systems.
  • Network with influencers in the fields of metabolic disease, oncology, and toxicology
  • Share how you are applying 3D cell-based technology in your work by submitting an abstract for a poster or oral presentation. 

organs-on-Chip Networks

Human Disease Modeling

Alternatives to Animal testing

Drug Safety Screening

Featured Speakers

This year’s program includes talks by innovators in 3D cell technologies from Novo Nordisk, Roche, Johns Hopkins University Center for Alternatives to Animal Testing, and Promega Corporation. 

Thomas Hartung, PhD

Dr. Hartung is a professor at Johns Hopkins Bloomberg School of Public Health and Director of the Johns Hopkins University Center for Alternatives to Animal Testing (CAAT). The main goal of Dr. Hartung’s work is to catalyze a paradigm shift in toxicity testing to improve public health. Due to his

Olivier Frey, PhD

Olivier Frey is Head of Technologies & Platforms and Project Manager of Microphysiological Systems at InSphero AG, and is the former group leader of the Bio Engineering Laboratory of ETHZ (Swiss Federal Institute of Technology in Zürich). He holds a Dr.Sc in Microtechnology from the École Polytechnique Fédérale de Lausanne

Armin Wolf, Prof., Phd

Prof. Armin Wolf is a Professor of Toxicology at the Technical University of Kaiserslautern, Germany, and InSphero Chief Scientific Officer. He joined InSphero from Janssen Pharmaceuticals Inc. (a Johnson & Johnson company), where he was Senior Director and Global Head of the Mechanistic & Investigative Toxicology (MIT) group in Beerse

Matthias von Herrath, MD

Vice President and Head of the Novo Nordisk Diabetes R&D Center and Professor at the La Jolla Institute for Immunology.

Call for Abstracts

New Frontiers in 3D invites scientists, bioengineers, academic researchers, and innovation leaders to submit abstracts featuring innovative applications of 3D Cell Technology for consideration for poster and oral presentations at our 2021 meeting.  Check back for details and abstract submission guidelines.

Sponsorship Opportunities

New Frontiers in 3D plans to invite a select group of innovative 3D cell-based solution providers to sponsor our 2021 virtual meeting and showcase products that we believe will be of interest to scientists, researchers, regulatory agencies, and others in the field. If you haven’t already received an invitation to participate, contact us for more information.